Severe aortic stenosis (narrowing of the aortic valve) affects
more than 100,000 people in the United States. If left untreated,
about half the people with this condition will die within two
years. While the standard treatment option is open-heart valve
replacement, many patients are deemed ineligible or too high risk
for open-heart surgery.
OhioHealth was the first hospital system in Ohio to offer two,
non-surgical options for treating aortic stenosis. Catheter-based procedures like these are the future of heart valve replacement and offer many benefits. In particular, the non-invasive approach allows patients to avoid a large chest incision, which reduces the risk of complications and shortens recovery times.
Transcatheter Aortic Valve Replacement (TAVR)
For patients deemed inoperable for open-heart surgery, a new,
FDA-approved procedure -- transcatheter aortic valve replacement
(TAVR) -- is now available as an immediate treatment option at
Riverside Methodist. The Edwards SAPIEN Transcatheter Heart Valve
is used to replace the diseased native heart valve using a
Transcatheter aortic valve replacement (TAVR) procedures
take place in a "hybrid room," which is part operating room and part catheterization lab. Patients are managed by a team consisting
of a cardiovascular surgeon, an interventional cardiologist, an
anesthesiologist, an echocardiographer, a perfusionist and a staff
of nurses and radiology technicians.
A Second, Innovative Option for High-Risk Patients
The Medtronic CoreValve U.S. Pivotal Trial is the latest
non-surgical option for patients who need aortic valve
Going in through small incisions in the groin, the shoulder or
directly between the ribs, doctors can insert a bioprosthetic valve
through a catheter without removing the native valve.
OhioHealth is among a select group of leading U.S. hospitals
participating in the trial to evaluate this minimally invasive
alternative to open-heart surgery.